Psyence BioMedical (NASDAQ: BPM) has announced it has sourced a sustainable supply of high-potency iboga bark—through its strategic partner, closely held PsyLabs—a significant achievement as the company prepares for the clinical development of nature-derived ibogaine for substance use disorders.
According to Psyence, the collaboration with PsyLabs is an important step in securing a long-term supply of high-quality active pharmaceutical ingredients. PsyLabs’ ibogaine is fully GMP-compliant, ensuring it meets the rigorous standards required for clinical development.
In a statement, Jody Aufrichtig, CEO of Psyence, commented, “A reliable, ethically sourced supply of ibogaine is critical to our development pipeline. This achievement not only strengthens our ability to advance our ibogaine-based clinical programs but also positions Psyence BioMed as a global leader in the emerging ibogaine sector. As international interest in ibogaine continues to accelerate, securing a sustainable and culturally respectful supply chain gives us a meaningful competitive advantage and reinforces our commitment to scientific rigor, responsible innovation, and the preservation of traditional knowledge.”
Tony Budden, CEO of PsyLabs, added, “From soil to science, we will continue to ensure our ibogaine is not only the purest on the market, but the most ethically sourced. We’re building a new standard for what ethical psychedelic production can look like – where traditional knowledge holders are partners, not just suppliers.”
